SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5—11) actively enrolling with overall enrollment on track for completion in Q4 2026Received FDA Fast Track designation for SAB-142 in new-onset Stage 3 T1DOperational runway through 2028…

SABS

Related stories